The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus

Simon, Susanne; Joean, Oana; Welte, Tobias; Rademacher, Jessica

doi:10.1183/16000617.0034-2023

Cited by 20 publications

(4 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccination is proven to be an important preventive healthcare measure that enhances health outcomes and prevents infection-induced COPD exacerbation. Even with ongoing recommendations to vaccinate COPD patients, vaccination rates continue to fall below optimal levels in this patient group [ 21 ]. Furthermore, the diversity in the factors associated with decreased willingness to get vaccinated necessitates further research to help pinpoint these factors and develop interventions accordingly.…”

Section: Discussionmentioning

confidence: 99%

Evaluating Influenza Vaccination Practices among COPD Patients

Al-Qerem,

Jarab,

Eberhardt

et al. 2023

Vaccines

View full text Add to dashboard Cite

Chronic Obstructive Pulmonary Disease (COPD) stands as a global health concern linked to considerable morbidity and mortality. In Jordan, the prevalence of COPD is substantial, but research in this area is limited. Exacerbations of COPD can lead to severe outcomes, including hospitalization and increased cardiovascular risk. Influenza is a significant trigger of exacerbations in COPD patients, and vaccination is recommended. However, studies have shown negative attitudes towards the influenza vaccine. This cross-sectional study aimed to investigate the knowledge, attitudes, practices, and intentions of COPD patients in Jordan regarding influenza vaccination. Data were collected through a custom-designed questionnaire from 300 COPD patients. The study revealed low influenza vaccination rates, with forgetfulness and lack of knowledge about vaccine effectiveness being the main barriers. Higher knowledge and positive attitudes were associated with greater intention to vaccinate. To tackle these challenges, it is recommended to implement customized health education campaigns, foster collaborations with healthcare providers, and engage in community-focused initiatives to enhance acceptance of the influenza vaccine among COPD patients in Jordan. These findings underscore the importance of addressing knowledge gaps and negative attitudes to enhance vaccine uptake and improve health outcomes for COPD patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating Influenza Vaccination Practices among COPD Patients

Al-Qerem,

Jarab,

Eberhardt

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first study reporting real-world VE in this patient group. In September 2023, Simon et al stated in The European Respiratory Review, a well-regarded respiratory journal that is affiliated with the European Respiratory Society (ERS), that “there are no studies investigating COVID-19 vaccine effectiveness explicitly in COPD patients”, further strengthening the novelty of our results [ 12 ].…”

Section: Introductionmentioning

confidence: 81%

Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients: Lessons from the Delta Variant

Polivka,

Valyi-Nagy,

Szekanecz

et al. 2023

Vaccines

View full text Add to dashboard Cite

Although the COVID-19 pandemic is profoundly changing, data on the effect of vaccination and duration of protection against infection and severe disease can still be advantageous, especially for patients with COPD, who are more vulnerable to respiratory infections. The Hungarian COVID-19 registry was retrospectively investigated for risk of infection and hospitalization by time since the last vaccination, and vaccine effectiveness (VE) was calculated in adults with COPD diagnosis and an exact-matched control group during the Delta variant of concern (VOC) wave in Hungary (September–December 2021). For the matching, sex, age, major co-morbidities, vaccination status, and prior infection data were obtained on 23 August 2021. The study population included 373,962 cases divided into COPD patients (age: 66.67 ± 12.66) and a 1:1 matched group (age: 66.73 ± 12.67). In both groups, the female/male ratio was 52.2:47.7, respectively. Among the unvaccinated, there was no difference between groups in risk for infection or hospitalization. Regarding vaccinated cases, in the COPD group, a slightly faster decline in effectiveness was noted for hospitalization prevention, although in both groups, the vaccine lost its significant effect between 215 and 240 days after the last dose of vaccination. Based on a time-stratified multivariate Cox analysis of the vaccinated cases, the hazard was constantly higher in the COPD group, with an HR of 1.09 (95%: 1.05–1.14) for infection and 1.87 (95% CI: 1.59–2.19) for hospitalization. In our study, COPD patients displayed lower vaccine effectiveness against SARS-CoV-2 infection and hospitalization but a similar waning trajectory, as vaccines lost their preventive effect after 215 days. These data emphasize revaccination measures in the COPD patient population.

show abstract

“…Pharmacotherapy to prevent COPD exacerbation cannot be over-emphasized. Other preventive therapy such as vaccination to prevent pneumonia caused by other micro-organisms is another important strategy to be employed 19 .…”

Section: Discussionmentioning

confidence: 99%

Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity

Kwok,

Chau,

Tam

et al. 2024

Sci Rep

View full text Add to dashboard Cite

While studies have suggested increased risks of severe COVID-19 infection in chronic obstructive pulmonary disease (COPD), the persistent and delayed consequences of COVID-19 infection on patients with COPD upon recovery remain unknown. A prospective clinical study was conducted in Hong Kong to investigate the persistent and delayed outcomes of patients with COPD who had COVID-19 infection of different severity (mild-moderate COVID-19 and severe COVID-19), compared with those who did not. Chinese patients with COPD ≥ 40 years old were recruited from March to September 2021. They were prospectively followed up for 24.9 ± 5.0 months until 31st August 2023. The primary outcome was the deterioration in COPD control defined as the change in mMRC dyspnea scale. The secondary outcomes included the change in exacerbation frequency and non-COVID-19 respiratory mortality (including death from COPD exacerbation or bacterial pneumonia). 328 patients were included in the analysis. Patients with mild-moderate and severe COVID-19 infection had statistically significant increased risks of worsening of mMRC dyspnoea scale by increase in 1 score from baseline to follow-up with adjusted odds ratios of 4.44 (95% CI = 1.95–10.15, p < 0.001) and 6.77 (95% CI = 2.08–22.00, p = 0.001) respectively. Patients with severe COVID-19 infection had significantly increased risks of increase in severe COPD exacerbation frequency with adjusted odds ratios of 4.73 (95% CI = 1.55–14.41, p = 0.006) non-COVID-19 respiratory mortality from COPD exacerbation or pneumonia with adjusted hazard ratio of 11.25 (95% CI = 2.98–42.45, p < 0.001). After recovery from COVID-19, worsening of COPD control from worsening of dyspnea, increase in severe exacerbation frequency to non-COVID-19 respiratory mortality (COPD exacerbation and pneumonia) was observed among patients with severe COVID-19. Mild to moderate COVID-19 was also associated with symptomatic deterioration.

show abstract

The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus

Cited by 20 publications

References 137 publications

Evaluating Influenza Vaccination Practices among COPD Patients

Evaluating Influenza Vaccination Practices among COPD Patients

Waning of SARS-CoV-2 Vaccine Effectiveness in COPD Patients: Lessons from the Delta Variant

Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity

Contact Info

Product

Resources

About